# A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

> **NCT07126665** · PHASE1,PHASE2 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 116 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** MHB088C for Injection
- **DRUG:** MHB039A for Injection

## Key facts

- **NCT ID:** NCT07126665
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2029-08
- **Final completion:** 2031-08
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07126665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07126665, "A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07126665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*